Low-Dose Naltrexone (LDN) 0.5mg Oral Capsules

Low-dose naltrexone (LDN), considered in a daily dose of  0.5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signalling in addition to systemically upregulating endogenous opioid signalling by the transient opioid-receptor blockade.